Finerenone 是一种选择性、具有口服活性的、非甾体类盐皮质激素受体拮抗剂 (IC50=18 nM)。与糖皮质激素受体、雄激素受体和孕酮受体相比，它表现出良好的选择性 (>500-fold)。它在心肾疾病研究中具有潜在的应用前景，如 2 型糖尿病和慢性肾脏疾病。

Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the treatment of chronic heart failure. Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).

1050477-31-0

C21H22N4O3

378.43

BAY-948862;BAY 948862;BAY-94-8862;BAY 94-8862;BAY94-8862;BAY948862

DMSO:60 mg/ml (158.55 mM)
H2O:Insoluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years